Baveno VII criteria to predict decompensation in compensated advanced chronic liver disease: Still some shades of grey.
作者信息
Rodrigues Susana G
机构信息
Department of Visceral Surgery and Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
出版信息
Clin Mol Hepatol. 2023 Jan;29(1):110-112. doi: 10.3350/cmh.2022.0414. Epub 2022 Dec 12.
Abstract
摘要
相似文献
1
Baveno VII criteria to predict decompensation in compensated advanced chronic liver disease: Still some shades of grey.预测代偿期晚期慢性肝病失代偿的巴韦诺 VII 标准：仍存在一些灰色地带。
Clin Mol Hepatol. 2023 Jan;29(1):110-112. doi: 10.3350/cmh.2022.0414. Epub 2022 Dec 12.
2
Correspondence on Editorial regarding "Baveno-VII criteria to predict decompensation and initiate non-selective beta-blocker in compensated advanced chronic liver disease patients".关于“巴韦诺 VII 标准用于预测代偿期晚期慢性肝病患者失代偿及启动非选择性β受体阻滞剂治疗”的社论通信
Clin Mol Hepatol. 2023 Jan;29(1):188-190. doi: 10.3350/cmh.2022.0408. Epub 2022 Nov 22.
3
Validation of non-invasive diagnosis of CSPH in patients with compensated advanced chronic liver disease according to Baveno VII.根据 Baveno VII，验证非侵入性诊断代偿性晚期慢性肝病患者的 CSPH。
Liver Int. 2023 Sep;43(9):1966-1974. doi: 10.1111/liv.15632. Epub 2023 Jun 8.
4
Baveno-VII criteria to predict decompensation and initiate non-selective beta-blocker in compensated advanced chronic liver disease patients.贝文诺-七项标准预测代偿期慢性肝病患者失代偿并开始使用非选择性β受体阻滞剂。
Clin Mol Hepatol. 2023 Jan;29(1):135-145. doi: 10.3350/cmh.2022.0181. Epub 2022 Sep 5.
5
Evolving portal hypertension through Baveno VII recommendations.通过贝伐诺七项建议演变的门静脉高压症。
Ann Hepatol. 2024 Jan-Feb;29(1):101180. doi: 10.1016/j.aohep.2023.101180. Epub 2023 Nov 19.
6
ABC: a novel algorithm to stratify decompensation risk in patients with compensated advanced chronic liver disease (CHESS2108): an international, multicenter cohort study.ABC：一种新型算法，用于分层代偿期晚期慢性肝脏疾病（CHESS2108）患者的失代偿风险：一项国际性、多中心队列研究。
Hepatol Int. 2022 Oct;16(5):1105-1115. doi: 10.1007/s12072-022-10345-4. Epub 2022 May 24.
7
Baveno VII - Renewing consensus in portal hypertension.《巴韦诺 VII 共识：门静脉高压领域的新共识》
J Hepatol. 2022 Apr;76(4):959-974. doi: 10.1016/j.jhep.2021.12.022. Epub 2021 Dec 30.
8
A combined model based on spleen stiffness measurement and Baveno VI criteria to rule out high-risk varices in advanced chronic liver disease.基于脾脏硬度测量和 Baveno VI 标准的联合模型排除晚期慢性肝病高危静脉曲张。
J Hepatol. 2018 Aug;69(2):308-317. doi: 10.1016/j.jhep.2018.04.023. Epub 2018 May 3.
9
Do we need to re-define the Baveno VI elastography criteria for compensated advanced chronic liver disease (cACLD)?我们是否需要重新定义代偿期晚期慢性肝病（cACLD）的巴韦诺VI弹性成像标准？
J Hepatol. 2021 Sep;75(3):750-752. doi: 10.1016/j.jhep.2021.04.019. Epub 2021 Apr 20.
10
Reply to: "Do we need to re-define the Baveno VI elastography criteria for compensated advanced chronic liver disease (cACLD)?".回复：“我们是否需要重新定义代偿期晚期慢性肝病（cACLD）的巴韦诺VI弹性成像标准？”
J Hepatol. 2021 Sep;75(3):752-753. doi: 10.1016/j.jhep.2021.06.007. Epub 2021 Jun 17.
引用本文的文献
1
Evaluation of Noninvasive Tools for Predicting Esophageal Varices in Patients With Cirrhosis at Tygerberg Hospital, Cape Town.开普敦泰格堡医院对肝硬化患者食管静脉曲张预测的非侵入性工具评估
Int J Hepatol. 2024 Sep 11;2024:9952610. doi: 10.1155/2024/9952610. eCollection 2024.
2
Risk Factors for Progressive Fibrosis and Cirrhosis in Patients With Chronic Hepatitis C in India.印度慢性丙型肝炎患者发生进行性纤维化和肝硬化的危险因素
Cureus. 2024 Jul 15;16(7):e64550. doi: 10.7759/cureus.64550. eCollection 2024 Jul.
3
Red cell distribution width/platelet ratio estimates the 3-year risk of decompensation in Metabolic Dysfunction-Associated Steatotic Liver Disease-induced cirrhosis.红细胞分布宽度/血小板比值估计代谢相关脂肪性肝病相关性肝硬化失代偿的 3 年风险。
World J Gastroenterol. 2024 Feb 21;30(7):685-704. doi: 10.3748/wjg.v30.i7.685.
4
Role of Portosystemic Shunt and Portal Vein Stent in Managing Portal Hypertension Due to Hematological Diseases.门体分流术和门静脉支架在治疗血液系统疾病所致门静脉高压中的作用
Cureus. 2024 Feb 14;16(2):e54206. doi: 10.7759/cureus.54206. eCollection 2024 Feb.
本文引用的文献
1
Baveno-VII criteria to predict decompensation and initiate non-selective beta-blocker in compensated advanced chronic liver disease patients.贝文诺-七项标准预测代偿期慢性肝病患者失代偿并开始使用非选择性β受体阻滞剂。
Clin Mol Hepatol. 2023 Jan;29(1):135-145. doi: 10.3350/cmh.2022.0181. Epub 2022 Sep 5.
2
Non-invasive tests for clinically significant portal hypertension after HCV cure.慢性丙型肝炎治愈后临床显著门静脉高压的非侵入性检测。
J Hepatol. 2022 Dec;77(6):1573-1585. doi: 10.1016/j.jhep.2022.08.025. Epub 2022 Sep 5.
3
A Combined Baveno VII and Spleen Stiffness Algorithm to Improve the Noninvasive Diagnosis of Clinically Significant Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease.一种联合 Baveno VII 和脾脏硬度算法，以改善代偿期慢性肝病患者临床显著门静脉高压的无创诊断。
Am J Gastroenterol. 2022 Nov 1;117(11):1825-1833. doi: 10.14309/ajg.0000000000001887. Epub 2022 Jul 21.
4
Baveno VII - Renewing consensus in portal hypertension.《巴韦诺 VII 共识：门静脉高压领域的新共识》
J Hepatol. 2022 Apr;76(4):959-974. doi: 10.1016/j.jhep.2021.12.022. Epub 2021 Dec 30.
5
Noninvasive Diagnosis of Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease.代偿期慢性肝病患者门静脉高压的非侵入性诊断。
Am J Gastroenterol. 2021 Apr;116(4):723-732. doi: 10.14309/ajg.0000000000000994.
6
The cutoff of transient elastography for the evaluation of portal hypertension should be different according to the etiology?瞬时弹性成像评估门静脉高压症的截断值是否应根据病因不同而有所差异？
Clin Mol Hepatol. 2021 Jan;27(1):91-93. doi: 10.3350/cmh.2020.0311. Epub 2020 Dec 3.
7
Repeated FIB-4 measurements can help identify individuals at risk of severe liver disease.重复的 FIB-4 检测有助于识别发生严重肝脏疾病风险的个体。
J Hepatol. 2020 Nov;73(5):1023-1029. doi: 10.1016/j.jhep.2020.06.007. Epub 2020 Jul 1.
8
Spleen stiffness measurement for assessing the response to β-blockers therapy for high-risk esophageal varices patients.脾脏硬度测量用于评估高危食管静脉曲张患者对β受体阻滞剂治疗的反应。
Hepatol Int. 2020 Sep;14(5):850-857. doi: 10.1007/s12072-020-10062-w. Epub 2020 Jun 15.
9
Non-invasive response prediction in prophylactic carvedilol therapy for cirrhotic patients with esophageal varices.预防性应用卡维地洛治疗食管静脉曲张的肝硬化患者的非侵入性反应预测。
J Hepatol. 2019 Mar;70(3):412-422. doi: 10.1016/j.jhep.2018.10.018. Epub 2018 Oct 31.
10
Noninvasive tools and risk of clinically significant portal hypertension and varices in compensated cirrhosis: The "Anticipate" study.非侵入性工具与代偿性肝硬化临床显著门静脉高压和静脉曲张风险：“Anticipate”研究。
Hepatology. 2016 Dec;64(6):2173-2184. doi: 10.1002/hep.28824. Epub 2016 Oct 27.
Zotero 插件